fazarabine has been researched along with Lung Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Krynetskaia, NF; Krynetskiy, E; Mishra, AK; Phadke, MS | 1 |
| Crowley, JJ; Goodwin, JW; Livingston, RB; Panella, TJ; Williamson, SK | 1 |
1 trial(s) available for fazarabine and Lung Neoplasms
| Article | Year |
|---|---|
Phase II trial and cost analysis of fazarabine in advanced non-small cell carcinoma of the lung: a Southwest Oncology Group study.
Topics: Adult; Aged; Antineoplastic Agents; Azacitidine; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Middle Aged | 1995 |
1 other study(ies) available for fazarabine and Lung Neoplasms
| Article | Year |
|---|---|
Glyceraldehyde 3-phosphate dehydrogenase depletion induces cell cycle arrest and resistance to antimetabolites in human carcinoma cell lines.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Carcinoma; Cell Cycle; Cell Death; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Gene Knockdown Techniques; Glyceraldehyde-3-Phosphate Dehydrogenases; Humans; Lung Neoplasms | 2009 |